Share Price and Basic Stock Data
Last Updated: January 19, 2026, 1:57 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Centenial Surgical Suture Ltd operates in the Medical Equipment & Accessories industry, with a current market capitalization of ₹34.0 Cr and a share price of ₹93.2. The company’s revenue from operations has shown a fluctuating trend over recent quarters, with reported sales of ₹13.01 Cr in September 2022, rising slightly to ₹13.66 Cr by June 2023, before settling at ₹13.10 Cr in September 2023. Annual sales figures have displayed a modest recovery from ₹44.43 Cr in March 2022 to ₹52.66 Cr in March 2023, but are projected to drop to ₹51.19 Cr in March 2024 and recover to ₹53.49 Cr in March 2025. The trailing twelve months’ (TTM) sales stood at ₹51.91 Cr, indicating a slight contraction compared to previous years. This mixed revenue performance reflects the competitive landscape and potential challenges in scaling operations effectively. The company’s ability to navigate these fluctuations will be crucial for its sustainability in the medical equipment sector.
Profitability and Efficiency Metrics
Centenial Surgical Suture Ltd has reported a challenging profitability landscape, with a net profit of ₹-2.08 Cr for the latest period. The operating profit margin (OPM) has been relatively stable, recorded at 10.33%, but it has shown significant variability in previous quarters, with highs of 15.48% in March 2025 and lows of 6.15% in December 2024. The return on equity (ROE) stood at a low 4.64%, while the return on capital employed (ROCE) was even lower at 3.94%, reflecting inefficiencies in utilizing capital for generating profits. The cash conversion cycle (CCC) of 895.19 days indicates a prolonged process in managing receivables and inventory, which could hinder liquidity. The interest coverage ratio (ICR) of 1.70x points to a precarious ability to meet interest obligations, further complicating the financial outlook. Overall, the company’s profitability metrics highlight significant challenges that need addressing to enhance operational efficiency.
Balance Sheet Strength and Financial Ratios
As of the latest reporting, Centenial Surgical Suture Ltd’s balance sheet exhibits some vulnerabilities, evidenced by total borrowings of ₹10.81 Cr against reserves of ₹25.27 Cr. The debt-to-equity ratio is measured at 0.39, suggesting a moderate reliance on debt financing. The current ratio stands at a healthy 1.98, indicating adequate short-term liquidity to meet obligations. However, the quick ratio of 0.61 raises concerns about immediate liquidity, as it implies potential difficulties in covering current liabilities without relying on inventory liquidation. The company’s book value per share, including revaluation reserves, is ₹56.70, which is significantly higher than the current share price, suggesting that the stock may be undervalued. Financial ratios such as the interest coverage ratio (ICR) show a declining trend, which may pose risks in maintaining financial stability amidst increasing costs. Overall, while some parameters indicate strength, the rising debt levels and liquidity concerns merit close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Centenial Surgical Suture Ltd reveals a dominant public ownership at 53.11%, while promoter holdings stand at 46.89%. This distribution indicates a relatively balanced ownership structure, potentially fostering investor confidence. The number of shareholders has seen a gradual increase, reported at 1,193 as of September 2025, suggesting a growing interest in the company. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may signal a lack of institutional backing, which could impact the stock’s liquidity and perceived stability. The promoter holding has remained steady over the past year, reflecting commitment to the company’s long-term vision. Nevertheless, the low percentage of institutional investment could hinder the company’s ability to attract significant capital for expansion or innovation, which are critical in the competitive medical devices market.
Outlook, Risks, and Final Insight
Looking ahead, Centenial Surgical Suture Ltd faces both opportunities and challenges. The potential for revenue growth exists, particularly if the company can enhance operational efficiencies and optimize its supply chain to reduce the cash conversion cycle. However, risks such as declining profitability and increased debt levels could pose significant hurdles. The ongoing pressure on the medical equipment sector, combined with the company’s weak ROE and ROCE, necessitates strategic initiatives to improve financial performance. If the company can leverage its reserves effectively while managing costs, it may stabilize and grow. Conversely, failure to address these issues could lead to further financial distress. Investor sentiment will likely hinge on the company’s ability to demonstrate a turnaround in profitability and operational efficiency, crucial for regaining market confidence and enhancing shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 68.6 Cr. | 54.7 | 114/46.0 | 15.6 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 35.0 Cr. | 95.8 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 27.1 Cr. | 18.8 | 25.0/13.3 | 13.1 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 15,932 Cr. | 1,572 | 2,938/1,554 | 44.0 | 288 | 0.22 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 67.5 Cr. | 37.0 | 76.0/36.2 | 20.2 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 15,932.00 Cr | 355.66 | 23.23 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.01 | 13.13 | 13.02 | 13.66 | 13.10 | 12.38 | 12.05 | 13.74 | 14.27 | 12.20 | 13.31 | 12.94 | 13.46 |
| Expenses | 11.98 | 12.06 | 11.92 | 12.50 | 11.96 | 11.19 | 10.54 | 12.02 | 12.54 | 11.45 | 11.25 | 11.71 | 12.07 |
| Operating Profit | 1.03 | 1.07 | 1.10 | 1.16 | 1.14 | 1.19 | 1.51 | 1.72 | 1.73 | 0.75 | 2.06 | 1.23 | 1.39 |
| OPM % | 7.92% | 8.15% | 8.45% | 8.49% | 8.70% | 9.61% | 12.53% | 12.52% | 12.12% | 6.15% | 15.48% | 9.51% | 10.33% |
| Other Income | 0.08 | 0.02 | 0.03 | 0.01 | 0.02 | 0.06 | 0.03 | 0.00 | 0.06 | 0.01 | 0.05 | 0.00 | 0.05 |
| Interest | 0.39 | 0.39 | 0.52 | 0.48 | 0.52 | 0.51 | 0.95 | 0.53 | 0.53 | 0.50 | 2.19 | 0.32 | 0.46 |
| Depreciation | 0.31 | 0.34 | 0.31 | 0.30 | 0.32 | 0.33 | 0.44 | 0.79 | 1.09 | 1.11 | 1.26 | 0.95 | 0.99 |
| Profit before tax | 0.41 | 0.36 | 0.30 | 0.39 | 0.32 | 0.41 | 0.15 | 0.40 | 0.17 | -0.85 | -1.34 | -0.04 | -0.01 |
| Tax % | 26.83% | 22.22% | 53.33% | 25.64% | 28.12% | 24.39% | -26.67% | 25.00% | 23.53% | 0.00% | -11.19% | 0.00% | 0.00% |
| Net Profit | 0.30 | 0.28 | 0.14 | 0.29 | 0.24 | 0.31 | 0.19 | 0.30 | 0.13 | -0.85 | -1.18 | -0.04 | -0.01 |
| EPS in Rs | 0.82 | 0.77 | 0.38 | 0.79 | 0.66 | 0.85 | 0.52 | 0.82 | 0.36 | -2.33 | -3.23 | -0.11 | -0.03 |
Last Updated: December 27, 2025, 3:02 pm
Below is a detailed analysis of the quarterly data for Centenial Surgical Suture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 13.46 Cr.. The value appears strong and on an upward trend. It has increased from 12.94 Cr. (Jun 2025) to 13.46 Cr., marking an increase of 0.52 Cr..
- For Expenses, as of Sep 2025, the value is 12.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.71 Cr. (Jun 2025) to 12.07 Cr., marking an increase of 0.36 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.23 Cr. (Jun 2025) to 1.39 Cr., marking an increase of 0.16 Cr..
- For OPM %, as of Sep 2025, the value is 10.33%. The value appears strong and on an upward trend. It has increased from 9.51% (Jun 2025) to 10.33%, marking an increase of 0.82%.
- For Other Income, as of Sep 2025, the value is 0.05 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.05 Cr., marking an increase of 0.05 Cr..
- For Interest, as of Sep 2025, the value is 0.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.32 Cr. (Jun 2025) to 0.46 Cr., marking an increase of 0.14 Cr..
- For Depreciation, as of Sep 2025, the value is 0.99 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.95 Cr. (Jun 2025) to 0.99 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Jun 2025) to -0.01 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Jun 2025) to -0.01 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.03. The value appears strong and on an upward trend. It has increased from -0.11 (Jun 2025) to -0.03, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 53.49 | 51.91 |
| Expenses | 46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 47.07 | 46.48 |
| Operating Profit | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 6.42 | 5.43 |
| OPM % | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 12.00% | 10.46% |
| Other Income | 0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.12 | 0.11 |
| Interest | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 3.90 | 3.47 |
| Depreciation | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 4.25 | 4.31 |
| Profit before tax | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | -1.61 | -2.24 |
| Tax % | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | -9.32% | |
| Net Profit | 1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | -1.46 | -2.08 |
| EPS in Rs | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | -4.00 | -5.70 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 7.26% | -18.75% | 10.26% | -10.47% | 31.17% | -35.64% | -26.15% | -34.38% | 41.27% | 26.97% | -229.20% |
| Change in YoY Net Profit Growth (%) | 0.00% | -26.01% | 29.01% | -20.72% | 41.63% | -66.81% | 9.49% | -8.22% | 75.64% | -14.30% | -256.17% |
Centenial Surgical Suture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -287% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 29% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:36 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
| Reserves | 13.83 | 15.79 | 17.35 | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 | 25.33 | 25.27 |
| Borrowings | 11.32 | 12.28 | 13.11 | 15.24 | 14.37 | 13.10 | 12.72 | 13.47 | 9.30 | 9.92 | 23.24 | 30.01 | 10.81 |
| Other Liabilities | 19.53 | 21.80 | 16.68 | 16.07 | 14.89 | 15.61 | 27.96 | 27.00 | 21.85 | 25.40 | 23.70 | 23.83 | 41.78 |
| Total Liabilities | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.59 | 83.28 |
| Fixed Assets | 4.53 | 4.13 | 3.64 | 3.71 | 3.80 | 4.08 | 10.44 | 8.97 | 7.60 | 6.46 | 12.77 | 19.99 | 18.68 |
| CWIP | 0.19 | 0.19 | 0.19 | 0.19 | 0.22 | 0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 45.38 | 50.97 | 48.73 | 51.90 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | 64.60 | 64.60 |
| Total Assets | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.59 | 83.28 |
Below is a detailed analysis of the balance sheet data for Centenial Surgical Suture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.42 Cr..
- For Reserves, as of Sep 2025, the value is 25.27 Cr.. The value appears to be declining and may need further review. It has decreased from 25.33 Cr. (Mar 2025) to 25.27 Cr., marking a decrease of 0.06 Cr..
- For Borrowings, as of Sep 2025, the value is 10.81 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 30.01 Cr. (Mar 2025) to 10.81 Cr., marking a decrease of 19.20 Cr..
- For Other Liabilities, as of Sep 2025, the value is 41.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.83 Cr. (Mar 2025) to 41.78 Cr., marking an increase of 17.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 83.28 Cr.. The value appears to be improving (decreasing). It has decreased from 84.59 Cr. (Mar 2025) to 83.28 Cr., marking a decrease of 1.31 Cr..
- For Fixed Assets, as of Sep 2025, the value is 18.68 Cr.. The value appears to be declining and may need further review. It has decreased from 19.99 Cr. (Mar 2025) to 18.68 Cr., marking a decrease of 1.31 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 64.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.60 Cr..
- For Total Assets, as of Sep 2025, the value is 83.28 Cr.. The value appears to be declining and may need further review. It has decreased from 84.59 Cr. (Mar 2025) to 83.28 Cr., marking a decrease of 1.31 Cr..
Notably, the Reserves (25.27 Cr.) exceed the Borrowings (10.81 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.75 | -7.04 | -8.43 | -10.35 | -9.90 | -7.69 | -6.79 | -8.36 | -4.81 | -5.52 | -18.09 | -23.59 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 | 125.56 |
| Inventory Days | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 | 921.61 |
| Days Payable | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 | 151.98 |
| Cash Conversion Cycle | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 | 895.19 |
| Working Capital Days | 122.62 | 127.27 | 148.80 | 156.25 | 164.05 | 167.69 | 172.36 | 282.37 | 236.68 | 207.73 | 226.67 | 210.99 |
| ROCE % | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% | 3.94% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Diluted EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Cash EPS (Rs.) | 5.14 | 4.65 | 4.03 | 3.97 | 4.63 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Revenue From Operations / Share (Rs.) | 98.66 | 94.37 | 97.07 | 81.90 | 68.09 |
| PBDIT / Share (Rs.) | 11.77 | 9.46 | 8.16 | 8.28 | 9.40 |
| PBIT / Share (Rs.) | 3.92 | 6.90 | 5.76 | 5.47 | 6.54 |
| PBT / Share (Rs.) | -2.98 | 2.35 | 2.70 | 1.98 | 2.82 |
| Net Profit / Share (Rs.) | -2.70 | 2.09 | 1.63 | 1.16 | 1.77 |
| PBDIT Margin (%) | 11.92 | 10.02 | 8.40 | 10.11 | 13.80 |
| PBIT Margin (%) | 3.97 | 7.30 | 5.93 | 6.67 | 9.60 |
| PBT Margin (%) | -3.02 | 2.48 | 2.77 | 2.41 | 4.14 |
| Net Profit Margin (%) | -2.73 | 2.21 | 1.68 | 1.41 | 2.60 |
| Return on Networth / Equity (%) | -4.75 | 3.52 | 2.85 | 2.07 | 3.25 |
| Return on Capital Employeed (%) | 4.03 | 8.08 | 8.37 | 8.00 | 9.20 |
| Return On Assets (%) | -1.73 | 1.43 | 1.33 | 1.02 | 1.37 |
| Total Debt / Equity (X) | 0.39 | 0.44 | 0.31 | 0.30 | 0.41 |
| Asset Turnover Ratio (%) | 0.65 | 0.70 | 0.82 | 0.67 | 0.53 |
| Current Ratio (X) | 1.98 | 1.99 | 2.04 | 2.20 | 1.92 |
| Quick Ratio (X) | 0.61 | 0.69 | 0.76 | 0.86 | 0.77 |
| Inventory Turnover Ratio (X) | 1.24 | 0.50 | 0.58 | 0.45 | 0.46 |
| Interest Coverage Ratio (X) | 1.70 | 2.08 | 2.66 | 2.37 | 2.53 |
| Interest Coverage Ratio (Post Tax) (X) | 0.60 | 1.46 | 1.53 | 1.33 | 1.48 |
| Enterprise Value (Cr.) | 71.71 | 63.31 | 43.04 | 41.99 | 34.92 |
| EV / Net Operating Revenue (X) | 1.34 | 1.24 | 0.81 | 0.94 | 0.94 |
| EV / EBITDA (X) | 11.23 | 12.34 | 9.72 | 9.35 | 6.85 |
| MarketCap / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| Price / BV (X) | 1.94 | 1.54 | 1.08 | 1.09 | 0.78 |
| Price / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| EarningsYield | -0.02 | 0.02 | 0.02 | 0.01 | 0.04 |
After reviewing the key financial ratios for Centenial Surgical Suture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.14. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 5.14, marking an increase of 0.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 98.66. It has increased from 94.37 (Mar 24) to 98.66, marking an increase of 4.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.77. This value is within the healthy range. It has increased from 9.46 (Mar 24) to 11.77, marking an increase of 2.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.92. This value is within the healthy range. It has decreased from 6.90 (Mar 24) to 3.92, marking a decrease of 2.98.
- For PBT / Share (Rs.), as of Mar 25, the value is -2.98. This value is below the healthy minimum of 0. It has decreased from 2.35 (Mar 24) to -2.98, marking a decrease of 5.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 2. It has decreased from 2.09 (Mar 24) to -2.70, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 10.02 (Mar 24) to 11.92, marking an increase of 1.90.
- For PBIT Margin (%), as of Mar 25, the value is 3.97. This value is below the healthy minimum of 10. It has decreased from 7.30 (Mar 24) to 3.97, marking a decrease of 3.33.
- For PBT Margin (%), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 10. It has decreased from 2.48 (Mar 24) to -3.02, marking a decrease of 5.50.
- For Net Profit Margin (%), as of Mar 25, the value is -2.73. This value is below the healthy minimum of 5. It has decreased from 2.21 (Mar 24) to -2.73, marking a decrease of 4.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is -4.75. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to -4.75, marking a decrease of 8.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 8.08 (Mar 24) to 4.03, marking a decrease of 4.05.
- For Return On Assets (%), as of Mar 25, the value is -1.73. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to -1.73, marking a decrease of 3.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.39, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.70 (Mar 24) to 0.65, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.98, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.69 (Mar 24) to 0.61, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 4. It has increased from 0.50 (Mar 24) to 1.24, marking an increase of 0.74.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.70. This value is below the healthy minimum of 3. It has decreased from 2.08 (Mar 24) to 1.70, marking a decrease of 0.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 3. It has decreased from 1.46 (Mar 24) to 0.60, marking a decrease of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 71.71. It has increased from 63.31 (Mar 24) to 71.71, marking an increase of 8.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.34, marking an increase of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 11.23. This value is within the healthy range. It has decreased from 12.34 (Mar 24) to 11.23, marking a decrease of 1.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For Price / BV (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.94, marking an increase of 0.40.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.02, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Centenial Surgical Suture Ltd:
- Net Profit Margin: -2.73%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -4.75% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.61
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 23.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.73%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | F-29, MIDC, Murbad Thane Maharashtra 421401 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Majrekar | Managing Director & CEO |
| Ms. Anuradha Kashikar | Executive Director & CFO |
| Mr. Devraj T Poojary | Executive Director |
| Mr. Neel M Vora | Ind. Non-Executive Director |
| Mr. Ridhima B Limaye | Ind. Non-Executive Director |
| Mr. Akash S Modi | Ind. Non-Executive Director |
| Mr. Anuj V Shah | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Centenial Surgical Suture Ltd?
Centenial Surgical Suture Ltd's intrinsic value (as of 21 January 2026) is ₹31.18 which is 67.45% lower the current market price of ₹95.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹35.0 Cr. market cap, FY2025-2026 high/low of ₹189/82.2, reserves of ₹25.27 Cr, and liabilities of ₹83.28 Cr.
What is the Market Cap of Centenial Surgical Suture Ltd?
The Market Cap of Centenial Surgical Suture Ltd is 35.0 Cr..
What is the current Stock Price of Centenial Surgical Suture Ltd as on 21 January 2026?
The current stock price of Centenial Surgical Suture Ltd as on 21 January 2026 is ₹95.8.
What is the High / Low of Centenial Surgical Suture Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Centenial Surgical Suture Ltd stocks is ₹189/82.2.
What is the Stock P/E of Centenial Surgical Suture Ltd?
The Stock P/E of Centenial Surgical Suture Ltd is .
What is the Book Value of Centenial Surgical Suture Ltd?
The Book Value of Centenial Surgical Suture Ltd is 84.1.
What is the Dividend Yield of Centenial Surgical Suture Ltd?
The Dividend Yield of Centenial Surgical Suture Ltd is 0.00 %.
What is the ROCE of Centenial Surgical Suture Ltd?
The ROCE of Centenial Surgical Suture Ltd is 3.94 %.
What is the ROE of Centenial Surgical Suture Ltd?
The ROE of Centenial Surgical Suture Ltd is 4.64 %.
What is the Face Value of Centenial Surgical Suture Ltd?
The Face Value of Centenial Surgical Suture Ltd is 10.0.